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Abstract:  
Introduction: The development of clinically useful tracers for PET imaging is enormously 
challenging and expensive. The intranasal (IN) route of administration is purported to be a 
viable route for delivering drugs to the brain but has, as yet, not been investigated for the 
delivery of PET tracers. If the intranasal (IN) pathway presents a viable option, it extends the 
PET imaging field by increasing the number of tracers available for human use.  
Here we report the results of a rodent study testing the feasibility of the IN route to 
administer radiotracers for brain PET imaging.  
 
Methods: We used two different, well characterised, brain penetrant radiotracers, 
[
18
F]fluorodeoxyglucose ([
18
F]FDG) and [
18
F]fallypride, and aimed to evaluate the 
pharmacokinetics after administration of the tracers via the intranasal route, and contrast this 
to intravenous administration. Image acquisition was carried out after tracer administration 
and arterial blood samples were collected at different time intervals, centrifuged to extract 
plasma and gamma counted. We hypothesised that [brain region]:[plasma] ratios would be 
higher via the intranasal route as there are two inputs, one directly from the nose to the brain, 
and another from the peripheral circulation. To assess the feasibility of using this approach 
clinically, we used these data to estimate radiation dosimetry in humans. 
 
Results: Contrary to our hypothesis, in case of both radiotracers, we did not see a higher ratio 
in the expected brain regions, except in the olfactory bulb, that is closest to the nose. It 
appears that the radiotracers move into the olfactory bulb region, but then do not progress 
further into other brain regions. Moreover, as the nasal cavity has a small surface area, the 
extrapolated dosimetry estimations for intranasal human imaging showed an unacceptably 
high level (15 mSv/MBq) of cumulative skin radiation exposure.  
 
Conclusions: Therefore, although an attractive route for brain permeation, we conclude that 
the intranasal route would present difficulties due to non-specific signal and radiation 
dosimetry considerations for brain PET imaging.  
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Introduction: 
The intranasal (IN) route of administration has been employed considerably well for drugs 
that are needed locally at the site of action, for example, the nasal passage, sinuses or lungs, 
and in some cases where rapid action is required, i.e., midazolam for epilepsy [1].  Since the 
1990’s there have been several studies assessing the validity of delivering drugs to the brain 
via the IN route, by-passing the blood brain barrier (BBB) with varying results [2–6]. 
However, irrespective of the extensive debates about a ‘direct nose to brain’ pathway [7–10],  
there has been a surge in the experimental use of IN administration of drugs and biologicals 
that do not cross the blood brain barrier when administered systemically. Some examples are 
peptides like insulin, for the treatment of Alzheimer’s disease [3], and oxytocin, for various 
neurodevelopmental disorders [11,12] and schizophrenia [13,14]. Another example, 
esketamine, an IN preparation of S-ketamine for the treatment of unipolar treatment resistant 
depression [15] that is currently undergoing clinical trials as a viable alternative to 
intravenous (IV) administration. Although ketamine does cross the blood brain barrier when 
given IV, this is not a practical route for conditions that require prolonged treatment.  
 
Assuming that IN administration allows brain entry for molecules that do not ordinarily cross 
the BBB at biologically relevant concentrations, we purported that this route might provide a 
useful alternative for delivery of tracers for the brain positron emission tomography (PET) 
imaging. The advantages of IN over IV route for PET imaging includes utilisation of tracers 
that undergo significant first pass metabolism, tracers that cause changes in blood flow or 
vasculature and large molecular weight peptides. On the other hand, it is clear that the IN 
route would also suffer disadvantages including lack of delivery precision, challenging 
kinetic modelling as well as the limitations related to radiation dosimetry. However, before 
investigating larger radiolabelled peptides or molecules that do not ordinarily cross the BBB, 
we decided to take a look at how radiotracers that are known to cross the BBB behave in the 
instance that we administered them intranasally. We believed that this ‘best-case’ scenario 
important as it would allow us to assess IN administration in a quantitative manner. Testing a 
brain impermeable tracer in such a way would present a difficulty in interpretation if there 
was no discernible signal, for two reasons: first, where the tracer doesn’t get into the brain at 
all, or the second, where it does, but the signal to noise ratio does not allow for a quantifiable 
image. Therefore, we designed a rodent study and chose two well-characterised, brain-
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penetrant radiotracers, [
18
F]fluorodeoxyglucose ([
18
F]FDG) and [
18
F]fallypride, that have 
different tracer characteristics, in order to compare their blood brain barrier permeability and 
kinetics after IN and IV administrations. 
 
[
18
F]FDG is a radiopharmaceutical glucose analogue (molar mass 181.15 g/mol) that gets 
taken up as glucose by metabolically active cells. Due to the lack of the 2-hydroxyl 
functional group however, once up taken it cannot be metabolised through glycolytic 
pathway, and therefore remains trapped in cells until radioactive decay [16]. When 
administered IV to healthy volunteers or rodents it accumulates globally throughout the brain. 
In contrast, [
18
F]fallypride (molar mass 364.45 g/mol) is a high affinity dopaminergic (D2/D3) 
receptor antagonist, and as such has the highest uptake in the basal ganglia in normal 
subjects. Additionally, it also undergoes metabolism and the parent fraction needs to be 
separated from the radioactive metabolites for accurate quantification.  
 
How drugs and biologicals move from the nasal cavity into the brain has also been the 
subject of much scholarship. For details the interested reader should see excellent reviews by 
Suman 2013 [17], Dhuria et al., 2009 [9], Lochhead and Thorne 2012 [10], Illum 2004 [8], 
and more recently by Crowe et al., 2018 [18]. Briefly, molecules from the nose may move 
through intracellularly through the olfactory and/or trigeminal nerves into the brain, or via 
paracellular pathways, through spaces between the nerves, to access the brain. As the nasal 
cavity is highly vascularised, molecules administered to the nose will also be absorbed into 
blood circulation and the lymphatic system. For those molecules that do not ordinarily cross 
the BBB, there will be none or negligible access to the brain via peripheral circulation. 
However, for molecules that can cross the BBB, there would thus be two pathways to the 
brain: one directly from the nose to the brain via one of the aforementioned routes, and the 
second via the peripheral circulation [18,19]  (Fig. 1). 
 
[Insert Fig. 1] 
 
 
 
In this study, as we have selected two BBB permeable tracers, [
18
F]FDG and [
18
F]fallypride, 
we expected that both tracers will access the brain ‘directly’ via the nasal cavity as well as 
‘indirectly’ after entering the peripheral circulation. Therefore, we hypothesise that the 
radiotracer concentration, relative to plasma, would be higher for IN than for IV 
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administration in the target brain region. More specifically, after IN administration, we would 
expect a higher plasma-corrected, quantitative uptake of [
18
F]FDG globally in the brain, and 
in the basal ganglia for [
18
F]fallypride, compared to IV administration, which would indicate 
that IN administration is a viable for brain PET imaging. 
 
Materials and Methods: 
Rats 
All experiments were conducted in accordance with the Home Office Animals (Scientific 
procedures) Act, UK, 1986 and were approved by the King’s College London ethical review 
committee. Adult (62.1 ± 6.7 days postnatal), male Sprague–Dawley rats (297 ± 44 g, 
Charles River, UK) were group-housed at 21 ± 1 C in a 12-h light:dark cycle and with ad 
libitum access to standard rat chow and drinking water. Animals were housed for a minimum 
of one week prior to any experimental procedures. For the [
18
F]FDG experiments, the rats 
were fasted 18 hours prior to the experiment. We used 4-7 per group for the [
18
F]FDG 
experiments and 5 rats per group for the [
18
F]fallypride experiments. The reporting of this 
study complies with the Animal Research: Reporting in vivo experiments (ARRIVE) 
guidelines (https://www.nc3rs.org.uk/arrive-guidelines) [20,21].  
Radiochemistry 
[
18
F]Fallypride was prepared by reacting the starting material tosylate (2–3 mg) with 
resolubilized K[
18
F]F/K222/K2CO3 in acetonitrile (1 mL) at 80 °C for 15 min using the Eckert 
& Ziegler Modular-lab system. The starting material tosyl-fallypride (2.0 mg) was purchased 
from ABX. [
18
F]Fallypride was purified by a semipreparative HPLC method using Onyc 
monolithic C18 (100 x 10 mm) and eluent 16:84 ethanol:H2O (NaH2PO4 0.05 M). HPLC 
product fraction was filtered through a sterile membrane filter into a vented sterile sample 
vial containing 5 mL of saline. The average radiochemical yield was 20% at end-of-delivery 
(EOD). A sample of solution containing [
18
F]fallypride was analysed by an analytical HPLC 
method using Luna C18 (250 x 4.6 mm,  5 μm) and eluent 52:48 H2O (0.1 M Ammonium 
formate and 0.052 mM acetic acid):acetonitrile for the determination of molar activity, 
radiochemical purity (>99%) and chemical purity (>99%). The molar activity ranged from 
179 ± 76 GBq/mol, decay corrected to end-of-delivery. 
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[
18
F]FDG was synthesized using 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethanesulfonyl-beta-D-
mannopyranose as precursor and synthesized on a GE TracerLab MX Synthesizer as 
previously described [22].  
 
Surgical procedure 
Anaesthesia was induced with isoflurane (5% in oxygen) and maintained on 2% isoflurane in 
oxygen at a flow rate of 1 mL/min. The femoral vein and artery were surgically exposed and 
a cannula was placed into the vein (Linton Instruments #BPE-T60) and the artery (Linton 
Instruments # BPE-T50). The rats were then randomly allocated to receive the tracer either 
intranasally or intravenously.  
 
Tracer administration  
For the IN administration, a 0.3 mL insulin syringe (BD #ND890) was fitted with a PE10 
cannula (15 mm) such that it covered approximately 3 mm of the needle tip. 20 L of 
radiotracer was administered into each nare as rapidly as possible (approximately within one 
minute) and the syringe radioactivity measured before and after administration to calculate 
the injected dose. 
Pilot studies showed that a 30 minutes after IN administration was the optimal time-point in 
terms of image resolution for [
18
F]FDG. Therefore, the average time for the start of the PET 
acquisition was 33±0.8 minutes after IN administration. Although our pilot study ascertained 
that [
18
F]fallypride should be IN administered immediately before acquisition, our actual time 
delay between administration and the start of acquisition was 10.3±2.6 minutes. This was due 
to the time taken to move and position the animal in the scanner, having administered it on 
the bench (to avoid scanner contamination). 
 
The IV administration of radiotracers was carried out via the femoral vein cannula and there 
was no lag between the injection and start of the acquisition. However, prior to the tracer 
administration, these ‘IV rats’ were kept under anaesthesia for an additional period of time 
(~33 mins for [
18
F]FDG and ~ 10 mins for [
18
F]fallypride) to match the total time spent under 
anaesthesia for ‘IN rats’ (Fig. 2).  
 
[Insert Fig. 2] 
 
 
 
PET/CT acquisition and reconstruction 
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Rats were placed in a supine position and scanning was carried out using a BioScan 
nanoPET-CT
Plus 
(Mediso, Hungary) scanner. Dynamic PET scans were performed on a single 
volume of interest, and images were acquired over 45 mins and 60 mins for [
18
F]FDG and 
[
18
F]fallypride, respectively. The scans were obtained at 400-600 keV energy window, 5 ns 
coincidence time and coincidence mode of 1-5. CT scan was performed at standard frame 
resolution (512 x 512 pixels), 55 kVP tube voltage, 600 ms of exposure time and 360 
projections.  
Reconstruction was carried out using ordered subset expectation maximisation (OSEM) 
iterative reconstruction algorithm (propriety software, Mediso Ltd); binning intervals 
4x15s;1x60s;1x180s;2x300s;3x900s for [
18
F]fallypride and 
4x15s;1x60s;1x180s;2x300s;2x900s for [
18
F]FDG. Corrections for decay, randoms, crystal 
dead time, detector normalisation and attenuation correction were implemented. Images were 
reconstructed with a voxel size of 0.25 × 0.25 × 0.25 mm
3
 for CT, and 0.4 × 0.4 × 0.4 mm
3
 
for PET. The PET and CT images were co-registered automatically. 
 
Image analyses  
Images were analysed using VivoQuant 2.0 (Invicro LLC) software. The 3D rat brain atlas 
template was used to determine brain region (11 regions including whole brain) specific 
tracer concentrations. For SUV quantification in the throat and nose the image quantification 
was carried out using PMOD version 3.7 (PMOD Technologies LLC, Switzerland).  
Standardised uptake values (SUV) (g/mL) were calculated by dividing the image derived 
concentration with the ratio of the injected dose to the body weight. For the assessment of 
dose remaining in the nasal cavity (Fig. 6), the image derived SUV was normalised, whereby 
the highest value was fixed at 100%.  
 
Blood sampling and processing 
Arterial blood samples were collected in EDTA lined blood tubes (BD #367839) at specific 
time intervals after the administration of the tracer. 10 L of blood was removed for gamma 
counting before the sample was centrifuged (10,000 x g, 5 min, 4) to separate the plasma. 
Additionally, in case of [
18
F]fallypride, 50-100 L of plasma was removed and added to an 
equal volume of acetonitrile to precipitate the proteins. The sample was centrifuged (10,000 x 
g, 5 min, 4) to separate the supernatant from the protein precipitant. 100 L of the 
supernatant was removed and injected into a high-performance liquid chromatography 
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(HPLC) system (Agilent 1200 series) to separate the metabolites from the parent compound. 
The gradient used was as described in Peyronneau et al., 2013 [23].  Briefly, a Luna 5 μm 
C18(2) 100Å, 250 × 4.6 mm column (Phenomenex# 00G-4252-E0) was used. A linear 
gradient of 0-70% B over 20 minutes was applied using the mobile phases 0.1% v/v 
trifluoroacetic acid in water (A) and 0.1% v/v trifluoroacetic acid in acetonitrile (B) at a flow 
rate of 1 mL/min and 1 mL fractions were collected for the duration of the run. The fractions 
were counted, decay corrected and plotted in GraphPad Prism version 6h (San Diego) in 
order to calculate area under the curve.  
The plasma radioactive counts obtained were converted to MBq using a calibrated conversion 
scale, and %injected dose/g was calculated (%ID/g) for each time point. 
 
Calculation of Ratio for comparison between IN and IV administration routes 
As the scanning start time was not identical for IN and IV radiotracer administration (see Fig. 
2), all the imaging data, for both [
18
F]FDG and [
18
F]fallypride, were realigned and decay-
corrected to the time of tracer injection for each animal.  
To normalise the tracer tissue uptake with the blood tracer supply, the ratio between tissue 
and plasma tracer concentration was hence calculated for each region of interest (ROI) at 30-
45 minutes after tracer injection for [
18
F]FDG, and the time frames between 15-60 minutes  
after tracer injection for [
18
F]fallypride (Figs. 3 and 4 ).  
 
Dosimetry calculations for extrapolation to humans  
Dosimetry calculations were based on the administration of radioactive 
18
F-labelled 
compounds into the nasal cavity as extrapolated from the [
18
F]fallypride  rat experiments. 
The most common methods to calculate radionuclide dosimetry involve the use of the 
Medical Internal Radiation Dose (MIRD) schema. However, as the feasibility study described 
in this work involves a source of radiation in the nasal cavity (not a part of the standard 
MIRD schema), this method cannot be applied and thus other methods were investigated.  
 
Previous work using Monte Carlo simulations has determined absorbed skin dose rate 
conversion factors for a range of radionuclides, which subsequently allow the calculation of 
cumulated absorbed dose to the basal layer of the skin after a contamination event.[24,25] 
The cumulative skin dose can be expressed as: 
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𝐷𝑇 = 𝐷 ×
𝐴𝐷(1−𝑒
−𝜆𝑒𝑓𝑓Δ𝑇)
𝜆𝑒𝑓𝑓𝑒
(−𝜆𝑒𝑓𝑓Δ𝑇)
      Equation (1) 
   
 
Where DT represents total cumulated skin dose over an area of 1 cm
2
 (mSv), D represents the 
skin dose rate of a 1 cm
2
 contamination, averaged over an area of 1 cm
2
 (mSv/h/kBq); AD is 
the mean measured activity over 1 cm
2
 (kBq); λeff is the effective decay constant 
(=ln(2)/T1/2eff approximated here as standard physical decay only) and ΔT is the total 
exposure time (h). Extending the contamination methodology of the skin to the 
approximation of skin inside the nasal cavity, and on the assumption that upon IN 
administration [
18
F]fallypride covers the entire nasal cavity of an area of approximately 160 
cm
2
 [26], cumulative absorbed skin dose can thus be calculated via Equation (1).  
A conversion factor from previous work [27] gives an absorbed skin dose rate value for 
18
F-
based radiopharmaceuticals of 1.95 mSv/hr per kBq/cm
2
. In the case of IN administration of 
[
18
F]fallypride, the optimal uptake time from the rat experiments was 22.5 minutes. Dynamic 
scanning then takes approximately 40-60 minutes. For these preliminary dosimetry 
estimations, we thus assumed that the radiotracer was fixed in place in the nasal cavity for 1 
hour and calculated the skin dose accordingly.  
 
Statistics 
All data shown is mean ± standard deviation, unless otherwise mentioned. All statistical 
analyses were carried out using GraphPad Prism (version 6.0h), and p  0.05 was considered 
to be statistically significant. Two-way analysis of variance (ANOVA) with the Sidak 
correction for multiple comparisons was used to ascertain statistical significance where 
appropriate.  
For [
18
F]fallypride metabolism, data were analysed by using a nonlinear curve fit for one-
phase decay and a comparison of fits was carried out to detect differences. Differences in 
plasma radiotracer concentrations via the two routes were assessed using the students t-test.   
 
Results 
Higher plasma corrected uptake after IN administration in the olfactory bulb 
Comparing regional brain uptake for both tracers revealed that, relative to plasma radiotracer 
concentration, there were no significant differences between IV and IN administration, except 
in the olfactory bulb.  
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We had hypothesised that due to two inputs, IN administration should show greater uptake 
than IV administration, into the target brain areas regions (whole brain and basal ganglia for 
[
18
F]FDG and [
18
F]fallypride, respectively). However, the data demonstrate that this is not the 
case. Statistical testing revealed no significant effect of route of administration in either 
cases, [
18
F]FDG (p = 0.62) and [
18
F]fallypride (p = 0.38). Additional comparisons between 
the different brain regions (Fig. 3) for both routes showed that only the olfactory bulb had 
significantly higher uptake after IN administration.  
 
 [Insert Fig. 3.] 
 
 
 
Taken together, this suggests that in the given time frame, the uptake in the whole brain for 
[
18
F]FDG, and in the basal ganglia for [
18
F]fallypride, is entirely dependent on the peripheral 
circulation, except in the olfactory bulb. The nasal input into the whole brain is either 
negligible or does not occur, in spite of higher uptake into the olfactory bulb.  
 
SUV comparisons  
 
Figs. 4 (a-b) shows the time activity curves for IV administration of [
18
F]FDG and 
[
18
F]fallypride, in the whole brain and basal ganglia respectively, and Figs. 4 (c-d) shows the 
same for IN radiotracer administration. With both [
18
F]FDG and [
18
F]fallypride, we obtained 
quantifiable images after IN administration. However, the graphs are not directly comparable, 
as mentioned previously under the methods section. Therefore, bar graphs are plotted (Figs. 4 
e-f) showing SUV comparisons, corrected for time, between IN and IV administrations.  
[
18
F]FDG (Fig. 4e) showed a significantly lower uptake (p <0.0001) in case of the IN route, 
as expected. Only the olfactory bulb showed equivalent uptake, i.e., no significant difference 
(p= 0.25) in case of both routes, IV and IN.   
 
 
[Insert Fig. 4.]  
 
 
Interestingly, in the case of [
18
F]fallypride, although there is a trend of overall decreased 
uptake via IN administration, the two routes are not statistically different (p = 0.062), i.e., 
both administration routes are akin with regards to the brain uptake (Fig. 4f). Regionally, the 
olfactory bulb shows a significantly higher uptake (p = 0.0082) for IN administration, 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
whereas the basal ganglia shows a slight decrease in uptake (p = 0.042), but the difference 
with IN administration, overall, is not as apparent as in the case of [
18
F]FDG (Fig. 4e).  
However, as the ratio ([brain uptake]:[plasma concentration]) was also independent of route 
of administration (Fig. 3b), we expect that correspondingly, the plasma concentration of the 
[
18
F]fallypride should be equivalent for both administration routes.  
 
Plasma radiotracer concentrations 
When we compared plasma radiotracer concentrations at the same time points as those used 
for SUV and ratio calculations, we observed no significant differences in metabolism (Fig. 
5a) and in the plasma concentration of [
18
F]fallypride (Fig. 5b) via the IN and IV routes. 
Plasma [
18
F]FDG concentration, however, was significantly lower (p <0.0001) when 
administered IN (Fig. 5c). 
Taken together, this suggests that in the case of intranasally administered [
18
F]fallypride, 
there is substantial, rapid absorption into the peripheral circulation. This is not the case with 
[
18
F]FDG, for which only a significantly smaller proportion gets absorbed into the periphery. 
Therefore, after IN administration, the brain uptake (excluding olfactory bulb) in case of 
[
18
F]fallypride is almost entirely supplied from the peripheral circulation rather than the nasal 
cavity (see Fig. 1).  
 
[Insert Fig. 5] 
 
 
Activity remaining in the nasal cavity after IN administration 
 
Fig. 6 shows the image derived, normalised TACs for the radioactivity retained in the nasal 
cavity for the duration of the scan. In case of [
18
F]FDG , the tracer reduces by only ~30% 
over the 45 minute scan duration (Fig. 6a), whereas for [
18
F]fallypride the reduction from the 
start to the end of the 60 minute scan is ~80%. This is in line with the previous results 
showing that a significant proportion of [
18
F]fallypride gets absorbed into the peripheral 
circulation, whereas [
18
F]FDG remains trapped in the nasal cavity.  
  
Dosimetry extrapolations from  
As described previously in the methods (see section on ‘Dosimetry calculations’), Equation 1 
can be used to calculate cumulative skin dose. Assuming a worst-case scenario, that the 
radiotracer remains in place for 1 hour, the cumulative skin dose can be calculated depending 
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on the activity that remains trapped in the nasal cavity. Fig. 6c demonstrates that for a known 
activity remaining in the nasal cavity, the absorbed radiation dose increases linearly. For 
example, for a trapped activity of 200 MBq, a cumulative skin dose, assuming 160 cm
2 
as the 
total surface area exposed in humans [26], a radiation dose of 3000 mSv can be reached.  
 
[Insert Fig. 6] 
 
 
 
Discussion 
 
This novel, pilot study examined whether the IN route is a viable option for the 
administration of radiotracers to image the brain. Although other studies have looked at drug 
administration to the brain using radiolabelled compounds, this is the first study to look at the 
feasibility of this administration route for brain PET imaging. The utility of this route of 
administration would be immense as crossing the blood brain barrier poses a significant 
barrier to the development of new PET radiotracers.  
 
Based on this study, however, it can be reasoned that the IN radiotracer administration route 
would not be suitable for brain PET imaging in humans. We hypothesised that the plasma 
corrected uptake should be higher in the target regions for IN administration to be viable. As 
we observed a higher uptake only in the olfactory region, but not in the target region, it seems 
that radiotracer uptake into the brain was non-specific and localised to the area closest to the 
nasal cavity. In man, by virtue of a larger brain, the distance between the olfactory bulb and 
others is even larger than in rodents. Even if we did assume some movement through the 
brain parenchyma, or flow, the time taken to reach specific targets might be too slow for PET 
imaging.  
Secondly, the cumulative skin radiation doses attained in order to obtain suitable image 
quality for quantification might be prohibitively high and deemed unsafe. Although there are 
no formal radiation limits for exposure to patients (provided the exposure is ethically 
justified), the International Committee on Radiation Protection recommends an equivalent 
skin dose limit of 500 mSv per year in order to minimise deterministic effects (tissue 
reactions known to increase with radiation dose). From our simulations of radiation 
dosimetry in this work, this 500 mSv limit would be reached with a trapped activity in the 
nasal cavity of approximately 35 MBq. Based on extrapolation of the rat data, where only 
0.2% of the administered [
18
F]fallypride reaches the basal ganglia, 35 MBq administered 
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intranasally may not give a quantifiable signal in the basal ganglia. Therefore, the amount of 
radioactivity that can be safely administered intranasally will likely compromise the image 
quality, making brain PET imaging unlikely.  It is likely that we have been overcautious in 
making the dosimetry estimates as a proportion of radiotracer does move out of the nasal 
cavity into the circulation. We estimated the worst-case scenario where a 
18
F-labelled tracer 
remains in the nasal cavity for one hour. However, our data showed that this was not 
necessary the case (Figs. 6 a-b) and that although both [
18
F]FDG and [
18
F]fallypride remain 
in the nasal cavity, the latter would have a lower cumulative skin dose compared to 
[
18
F]FDG, as it gets rapidly absorbed into circulation. Efforts should be made to investigate 
this further using Monte Carlo simulations of radiation transport and dosimetry and 
computerised models of PET detection.  
 
A handful of studies have administered radiopharmaceuticals intranasally into human 
subjects with different aims. A few have assessed the distribution of 
11
C-labelled drugs when 
given via an intranasal spray and used activities in the range of 2.5-12 MBq [28,29]. One 
study by Okuyama 1997, administered 148 MBq of [
99m
Tc] to two volunteers intranasally to 
determine brain uptake as a surrogate marker for the integrity of the BBB [30]. He observed 
that there was uptake in one volunteer but not in the other, and therefore concluded that the 
integrity of the BBB was comprised in the volunteer that showed nose to brain uptake.  
 
One possible technical concern with our pilot study could be that the effects we were 
observing in the olfactory bulb were due to spill-over effect from the nasal cavity, rather than 
the uptake in the olfactory bulb, as the distance between the two is very small. Nevertheless, 
it is unlikely that the signal we observe in the olfactory bulb due to spill over in its entirety. 
Indeed, the kinetics of the radiotracer uptake and clearance in the olfactory bulb were 
different from that of the nasal cavity (supplementary Fig. 1). Had the effect been solely due 
to spill-over, the kinetics for both should have been identical, which was not the case. 
Moreover, there is evidence of uptake only in the olfactory bulb, and no other brain regions, 
in another study using a radiolabelled peptide [2]. The study showed that the signal in the 
olfactory bulb could be modulated by administering the peptide with or without cyclodextrin 
(an adjuvant used to increase brain uptake), without changing the total amount present in the 
nasal cavity [2]. Representative images showing the lateral view after IN administration of 
[
18
F]FDG and [
18
F]fallypride are shown in supplementary Fig. 2.  
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An interesting observation was that the regional brain uptake (excluding the olfactory bulb) 
for [
18
F]fallypride was relatively similar for both the IN and IV routes (Fig. 4f), but not in the 
case of [
18
F]FDG (Fig. 4e) where IN administration resulted in a significantly lower uptake. 
This divergence may be attributed to the difference in cellular dynamics of the two tracers, 
i.e., [
18
F]FDG gets trapped inside cells whereas [
18
F]fallypride does not. Therefore, a 
plausible explanation is that a large proportion of [
18
F]FDG gets metabolically trapped in the 
cells of the nasal cavity and therefore has significantly lower blood levels in case of IN 
administration (Fig. 5c). However, [
18
F]fallypride is not restricted by cellular trapping, and 
therefore seems to be rapidly absorbed into peripheral circulation (Fig. 5b) and then from the 
periphery into the brain tissues, resulting in comparable SUVs between the IN and IV routes. 
This suggests that cell residence time may also play an important role in the delivery of 
molecules from the nasal cavity into the brain. How this might affect the IN delivery of other 
molecules to the brain, especially ones that do not ordinarily cross the blood brain barrier, 
remains to be tested.  
 
In this study we used tracers that are already known to cross the blood brain barrier. As this is 
the first study of its kind, we believed it a good starting point to work out kinetics and image 
quality before moving to tracers that do not normally cross the blood brain barrier. This work 
shows that even for tracers that are BBB permeable, and have similar physicochemical 
properties, IN administration can show widely varying results. Indeed a study looking at all 
quantitative intranasal drug delivery experiments carried out between 1970-2014 (a total of 
73 publications) showed widely variable results [31]. Moreover, their analyses showed that 
there was no correlation between the physiochemical properties of the molecules and uptake 
into the brain [31]. To add to the complexities of IN administration, some studies have found 
evidence of higher uptake in non-olfactory regions, such as the midbrain and cerebellum [32], 
whereas other, like us, have found a higher uptake only to the regions closest to the nasal 
cavity [2,33].    It appears that there is no consensus to predict which molecules are likely to 
enter the brain, and how far beyond the olfactory bulb they might reach. Consequently, each 
molecule requires individual quantitative verification if it is to be administered via IN 
administration.  
  
To summarise, in spite of being a valuable route of administration for drugs that do not cross 
the BBB, this study concludes that the IN administration route is not a generally suitable 
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route for administering PET tracers in humans, although one cannot exclude that this route 
may work for specific molecules. 
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Figure legends 
 
Fig. 1  
Schematic of the theoretical pathway of radiotracer entry into the brain after (a) intravenous 
(IV) and (b) intranasal (IN) administration for BBB permeable radiotracers.  
 
Fig. 2 
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Schematic illustration of the procedure of radiotracer administration. (a) the methodology for 
the intravenous (IV) tracer administration and (b) the methodology for the intranasal (IN) 
tracer administration.  
 
Fig. 3  
The ratio of the regional radiotracer concentration to the plasma concentration is shown on 
the y-axis for (a) [
18
F]FDG and (b) [
18
F]fallypride for both intravenous (IV), in white, and 
intranasal (IN), in grey, administration. The bars represent the mean values and the error bars 
show the standard deviation. Two-way ANOVA showed no statistically significant difference 
between the two routes. Only the olfactory bulb shows a significantly higher uptake for both 
[
18
F]FDG (p<0.0001) and [
18
F]fallypride (p=0.0073) through intranasal compared to 
intravenous administration.  
 
Fig. 4  
Time activity curves for intravenous (IV) administration of [
18
F]FDG for the whole brain (a), 
and [
18
F]fallypride for the basal ganglia (b) are shown. The y-axis depicts the standardised 
uptake value (SUV) and time on the x-axis. The scan start time and radiotracer administration 
time are identical in case of the IV route. (c) And (d) show the time activity curves for 
intranasal administration of [
18
F]FDG for the whole brain and [
18
F]fallypride for the basal 
ganglia, respectively. The y-axis depicts the standardised uptake value (SUV) and time after 
intranasal administration (mins) is plotted on the x-axis. Please note that the scan start time 
differs from the radiotracer administration time (~ 33 mins and ~ 11 mins prior to scan start 
for [
18
F]FDG and [
18
F]fallypride, respectively. (e) And (f) show the SUV comparison, 
corrected for the delay, between intravenous (IV) in white, and intranasal (IN) administration 
in grey for [
18
F]FDG and [
18
F]fallypride, respectively. The bars represent the mean values 
and the error bars show the standard deviation. 
 
Fig. 5 
(a) [
18
F]fallypride metabolism over time. The y-axis shows the % of parent fraction in the 
plasma over time in minutes (x-axis), after intravenous and intranasal administrations. A 
single exponential decay curve fits both plots as no differences were observed in the 
metabolism of [
18
F]fallypride when administered intranasal compared to intravenous. (b-c) 
Graphs showing the average plasma levels as % injected dose per gram (%ID/g) on the y-axis 
of (b) [
18
F]fallypride at time 48.3±11.3 mins (intravenous) and 48.4±10.8 mins (intranasal) 
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after tracer administration and (c) [
18
F]FDG at 46.7±9.7 mins (intravenous) and 46.7±7.5 
mins (intranasal) 
 
Fig. 6  
Activity remaining in the nasal cavity over time for (a) [
18
F]FDG and (b) [
18
F]fallypride are 
graphed. The y-axis shows normalised image derived SUVs, and the x-axis shows the length 
of scan in mins. (c) Total cumulative skin dose to an area of 160 cm
2 
as a result of activity 
remaining in the nasal cavity, as calculated via Equation 1. 
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